LPCN Lipocine Inc.

NEUTRAL Impact: 3/10 8-K
Horizon days Filed Mar 4, 2026 Processed 2mo ago SEC 0001493152-26-008852
8-K context-dependent: Items 8.01
Latest settled — T+20d
LPCN ▼ -74.97% at T+20d
NEUTRAL call ✗ call lost -74.97% · α vs SPY -71.18% · entry $8.19 → $2.05
Next anchor: T+60d in 9d
Currently $2.24 · -72.65% from $8.19 entry
Entry anchored
Mar 4, 03:57 PM ET
via Databento tick
T+1d
-0.73%
call -0.73% · α +0.58%
$8.13
settled 3mo ago
T+5d
-1.71%
call -1.71% · α +0.53%
$8.05
settled 2mo ago
T+20d
-74.97%
call -74.97% · α -71.18%
$2.05
settled 7w ago
T+60d
call — · α —
in 9d

Price Chart

Loading chart...

Executive Summary

Lipocine Inc. (LPCN) filed a prospectus supplement to its existing sales agreement with A.G.P./Alliance Global Partners, authorizing the potential sale of up to $50 million in common stock through an at-the-market (ATM) equity offering. This is a routine capital-raising mechanism and does not indicate an immediate sale of shares.

Actionable Insight

Monitor for future 424B filings or company announcements, which would signal an actual drawdown from this ATM facility and provide details on pricing and volume. The mere authorization of the facility is not a trading event.

Key Facts

  • Lipocine Inc. (LPCN) filed a prospectus supplement on February 26, 2026.
  • The filing relates to an existing sales agreement with A.G.P./Alliance Global Partners, originally entered into on April 26, 2024.
  • The prospectus supplement authorizes the potential sale of up to $50,000,000 of common stock under the ATM program.
  • The filing includes a legal opinion on the validity of the shares to be sold.

Financial Impact

Up to $50,000,000 in potential future dilution, subject to market conditions and company discretion.

dilutionequity

Risk Factors

  • Future sales under this program will be dilutive to existing shareholders.
  • Sales are likely to occur when the stock price is rising, which could put downward pressure on the share price.

Market Snapshot

Exchange
Nasdaq

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-008852
Exhibit: ex5-1.htm0001493152-26-008852
Document: 0001493152-26-008852-index-headers.html0001493152-26-008852
Document: 0001493152-26-008852-index.html0001493152-26-008852
Document: 0001493152-26-008852.txt0001493152-26-008852
7 reports for LPCN
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +9.09%Apr 21, 2026
Filters
Rows
Reports for LPCN — sortable, filterable
Type Now
May 19, 2026
1d ago
8-K
NEUTRAL ★ 4/10
$2.22 awaiting T+5awaiting T+5$2.24 (+1.13%)
May 18, 2026
2d ago
8-K
NEUTRAL ★ 2/10
$2.29 awaiting T+5awaiting T+5$2.24 (−2.18%)
May 7, 2026
13d ago
8-K
BEARISH ★ 8/10
$2.39 $2.32▲ +2.93%▲ +4.43%$2.24 (+6.28%)
Apr 21, 2026
29d ago
8-K
BEARISH ★ 6/10
$2.42 $2.23▲ +7.85%▲ +7.91%$2.24 (+7.44%)
Apr 2, 2026
6w ago
8-K
NEUTRAL ★ 2/10
$2.05 $2.20▲ +7.32%▲ +3.70%$2.24 (+9.27%)
Apr 2, 2026
6w ago
8-K
BEARISH ★ 7/10
$2.05 $2.20▼ −7.32%▼ −3.70%$2.24 (−9.27%)
Mar 4, 2026
11w ago
8-K
NEUTRAL ★ 3/10
$8.19 $8.05▼ −1.71%▲ +0.53%$2.24 (−72.65%)
Showing 7 of 7

US Market Status

Market Closed — Opens Thu (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access